Dimethyl fumarate Mylan is a medicine used to treat multiple sclerosis (MS), a disease in which inflammation damages the protective insulation around nerves (demyelination) as well as the nerves themselves. It is used in adults and adolescents from 13 years of age with a type of MS known as relapsing\-remitting MS, where the patient has flare\-ups of symptoms (relapses) followed by periods of recovery (remissions). Dimethyl fumarate Mylan contains the active substance dimethyl fumarate and is a ‘generic medicine’. This means that Dimethyl fumarate Mylan contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU. The reference medicine for Dimethyl fumarate Mylan is Tecfidera.
Therapeutic Indication
Dimethyl fumarate Mylan is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (RRMS).
Therapeutic Area (MeSH)
ATC Code
L04AX07
ATC Item
N/A
Pharmacotherapeutic Group
Immunosuppressants
Active Substance (Summary)
INN / Common Names
EMA Name
Dimethyl fumarate Mylan
Medicine Name
Dimethyl fumarate Mylan
Aliases
N/ANo risk management plan link.